HIV/AIDS Drug Pricing & Pharmaceutical Company News
Drug Pricing: Overview
- Overview of Drug Pricing for Public Programs (PDF) (April 2010)
From Project Inform
- The Price Isn't Right (January 25, 2008)
BMS raises HIV/AIDS drug prices, refuses to engage with treatment activists.
In Housing Works AIDS Issues Update, from Housing Works
- Shape-Shifting: The Art of Drug Pricing (October 2007)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Research and Development Costs, Unplugged (May 2004)
A chart comparing the R&D costs of five antiretrovirals.
In TAGline, from Treatment Action Group
- Untangling the Economics of Drug Pricing (May 2004)
Transcript and slides of a talk by Joshua P. Cohen, a senior research fellow at the Tufts Center for the Study of Drug Development.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- An Overview of AIDS Drug Access in the United States (May 2004)
Transcript of a talk by Christine Lubinski, Executive Director of the HIV Medicine Association.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Defining the Impact of AIDS Drug Pricing on the Private Sector (May 2004)
Transcript and slides of a talk by Michael Allerton, HIV Operations Policy Coordinator at the Permanente Medical Group.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Defining the Impact of AIDS Drug Pricing on the Public Sector (May 2004)
Transcript and slides of a talk by Lanny Cross, Program Manager of the New York State AIDS Drug Assistance Program.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Paying for Life: The Issues Behind Drug Pricing (Summer 2003)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations (April 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Patient Care Squeezed by Soaring Drug Prices (April 2002)
An in-depth examination of the drug-pricing war raging in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Can We Reform the Drug Industry? (April 2002)
An e-mail discussion between an AIDS activist and a patent attorney.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Pricing: News & Analysis
- AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild (February 1, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- California: HIV/AIDS Group Petitioning for "Stop Runaway Drug Pricing" Ballot Measure (November 19, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Generic HIV Drugs Will Widen U.S. Treatment Net (August 24, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Gilead Warned by Democrats Over "Quad" Pricing (August 17, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Generic-Based Regimen in U.S. Could Save Nearly $1 Billion in First Year of Use (August 14, 2012)
From AIDSmeds.com
- Reducing Commodity Costs for ARVs Could Mean Providing Treatment to Millions More People (August 2, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Global Health Partnership Announces First-, Second-Line AIDS Drugs Price Reductions in Developing World (May 18, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
VIEW ALL ARTICLES
The Ritonavir (Norvir) Price Increase
- Abbott Agrees to Pay $52 Million in Class Action Suit (April 15, 2011)
In Bloomberg Businessweek
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Why Abbott Is Allowed to Manipulate GSK and BMS's AIDS Drug Prices (July 8, 2009)
From BNET
- Federal Appeals Court Rejects Lawsuit Against Abbott Laboratories Over Norvir Price Hike (July 7, 2009)
Abbott Laboratories was not taking advantage of its monopoly on HIV "booster" medications to unfairly raise the price of Norvir (ritonavir), a U.S. federal appeals court has ruled.
From Bloomberg.com
- Abbott Agrees to Settle Lawsuit Over Norvir Price Hike (August 1, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Glaxo Joins Lawsuit Against Abbott Over Price of Norvir (November 12, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Pharmacies, Drug Wholesaler File Lawsuit Against Abbott Over Norvir Price (October 30, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Wall Street Journal Examines Reason Abbott Increased Price of Antiretroviral Norvir (January 3, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aetna Files Lawsuit Against Abbott Over 400% Price Increase of Ritonavir (May 27, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- U.S. Government Holds Hearing on Generic Production of Ritonavir (May 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
VIEW ALL ARTICLES
Viewpoints
- Fund Studies, Not Lanyards: Rethinking Corporate Participation at IAC (July 30, 2012)
In Housing Works AIDS Issues Update, from Housing Works
 Tell Gilead to Reduce the Cost of HIV Medications Now! A Blog Entry by Kevin Maloney (March 5, 2012)
From TheBody.com
- Pharmaceutical Companies' Profit Protection Hurts Global AIDS Fight (July 27, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- The Fair Pricing Coalition Expresses Dismay at the Price of Merck's Newly Approved Hepatitis C Drug (May 17, 2011)
From Fair Pricing Coalition
- Brazil's Threat to Break Antiretroviral Patents Harms Global AIDS Research, Treatment, Chicago Tribune Says (July 6, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group
On TheBodyPRO.com
- "On the Take" Explores Money, Medicine and Corruption (October 10, 2004)
Former New England Journal of Medicine editor Jerome P. Kassirer's new book deeply criticizes the influence of pharmaceutical industry money on medicine.
In The Boston Globe
- Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms (September 2004)
Dr. Marcia Angell's new book blisteringly critiques the pharmaceutical industry.
In TAGline, from Treatment Action Group
- Allow Imported HIV/AIDS Drugs (April 23, 2004)
An op-ed article by Mubarak Dahir, editor of the Express Gay News in Fort Lauderdale, Fla.
In Washington Blade
- Opinion: The Looming Crisis in Drug Pricing (April 2002)
Project Inform's Martin Delaney says it's time to draw a line in the sand.
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
Advertisement
|
Email
Glossary
